pyrazolam was originally developed at hoffman-la roche in the 1970s and subsequently “rediscovered” and sold as a research chemical starting in 2012.
subjective effects include sedation, anxiety suppression, muscle relaxation, disinhibition, and euphoria. pyrazolam is reported to produce comparably greater amounts of sedation and less euphoria than other benzodiazepines, limiting its recreational use.
it should be noted that the sudden discontinuation of benzodiazepines can be potentially dangerous or life-threatening for individuals using regularly for extended periods of time, sometimes resulting in seizures or death. it is highly recommended to taper one’s dose by gradually lowering the amount taken each day for a prolonged period of time instead of stopping abruptly.
benzodiazepines are habit-forming and can produce mental and physical dependence with continued use. it is strongly advised to use harm reduction practices if using this substance.
history and culture
pyrazolam was originally developed by a team led by leo sternbach at hoffman-la roche in the 1970s and subsequently “rediscovered” and sold as a research chemical starting in 2012.
pyrazolam is a drug of the benzodiazepine class. benzodiazepine drugs contain a benzene ring fused to a diazepine ring, which is a seven membered ring with the two nitrogen constituents located at r1 and r4. bromine is bound to this bicyclic structure at r7. additionally, at r6 the bicylic core is substitued with a 2-pyridine ring. pyrazolam also contains a 1-methylated triazole ring fused to and incorporating r1 and r2 of its diazepine ring. pyrazolam belongs to a class of benzodiazepines containing this fused triazole ring, called triazolobenzodiazepines, distinguished by the suffix “-zolam”.
benzodiazepines produce a variety of effects by binding to the benzodiazepine receptor site and magnifying the efficiency and effects of the neurotransmitter gamma aminobutyric acid (gaba) by acting on its receptors. as this site is the most prolific inhibitory receptor set within the brain, its modulation results in the sedating (or calming effects) of pyrazolam on the nervous system.
the anticonvulsant properties of benzodiazepines may be, in part or entirely, due to binding to voltage-dependent sodium channels rather than benzodiazepine receptors.
pyrazolam is most selective for the α2 and α3 receptor subtypes. it is excreted by the body unchanged thus not interacting with liver enzymes like other benzodiazepines, meaning that its use in people with reduced liver function may be safer.